Andere Sprachen Aerovate Therapeutics, Inc.

Aktien

A3CTMQ

US0080641071

AVTE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
1,66 ^USD	-0,60 %		+6,41 %	-92,66 %

18.06.	Top-Mittagstiefs	MT
18.06.	AEROVATE THERAPEUTICS, INC. : Guggenheim gibt eine neutrale Bewertung ab	ZM

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC	21.06.
Top Midday Decliners	18.06.
Sector Update: Health Care Stocks Retreat Late Afternoon	17.06.
Sector Update: Health Care	17.06.
Top Midday Decliners	17.06.
Aerovate Therapeutics Plunges after Prospective Hypertension Medication Misses Targets in Phase 2 Study, Scraps More Testing	17.06.
Aerovate scraps late-stage study of lung disorder drug	17.06.
Aerovate scraps late-stage study for hypertension drug after mid-stage trial fails	17.06.
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension	17.06.
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2B Portion of Impahct Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension	17.06.
Aerovate Therapeutics : June 2024 Corporate Presentation	01.06.
Aerovate Therapeutics : May 2024 Corporate Presentation	21.05.
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference	21.05.
Aerovate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights	13.05.
Aerovate Therapeutics : May 2024 Corporate Presentation	02.05.
Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing	12.04.
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing	04.04.
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference	27.03.
Aerovate Therapeutics Q4 Loss Widens	25.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Aerovate Therapeutics, Inc.

Aktien

A3CTMQ

US0080641071

AVTE

Andere Sprachen

Filter